Fact checked by Marley Hall Medically reviewed by Marla Anderson, MD The Food and Drug Administration (FDA) granted priority review for Enhertu (fam-trastuzumab deruxtecan-nxki) in 2024. This drug ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will ...

In DESTINY-Breast03, around 10% of patients treated with Enhertu developed ILD or pneumonitis, compared to less than 2% of the Kadcyla group, although most of the cases were grade 1 and 2 and none ...

When LVEF is >45% and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is <10%, continue treatment with ENHERTU ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Enhertu has emerged as an important new treatment ... with the overall risk for all types at around 10% to 15%. The median overall survival (OS) for patients with breast cancer who have developed ...

Top-selling cancer medicine Tagrisso was a big driver with sales up 3.5% higher than expected, while revenue from newcomer ...

She says Enhertu would give her extra time with her ... He points to deals with 19 countries in Europe, and another 10 worldwide, including the US, Australia and Canada. Dr Rossi says the decision ...

A Long Islander with cancer could save thousands of dollars a year, while someone on less expensive medications may ...

ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...